Company / EPS (Diluted)
KalVista Pharmaceuticals, Inc. EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.44
FY2025
5-year range
-$3.69 / -$1.38
FY2021-FY2025
Trend
+6.8%
vs FY2024
Sector context
#154 of 204
Health Care
What the data says
KalVista Pharmaceuticals, Inc.'s eps (diluted) of $-3.44 is lower than 75% of companies in the Health Care sector (FY2025). EPS (Diluted) returned to growth in FY2025 after 3 years of decline, reaching $-3.44.
Based on SEC 10-K filings.
-3.44 in FY2025.
Remained stable around $-3.44 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 204This company -$3.44 Sector average -$0.98
▼
-251.2% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 6.8% year-over-year.
- Ranks #154 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2021.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.44 | +6.8% |
| FY2024 | -$3.69 | -7.3% |
| FY2023 | -$3.44 | -109.8% |
| FY2022 | -$1.64 | -18.8% |
| FY2021 | -$1.38 | +9.8% |
| FY2020 | -$1.53 | +65.8% |
| FY2019 | -$4.47 | +82.9% |
| FY2018 | -$26.17 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026